Literature DB >> 20389150

Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.

Randall K Leong1, Stefan G G De Wachter, Philip E V van Kerrebroeck.   

Abstract

The overactive bladder syndrome (OAB) negatively affects the daily life of many people. Conservative treatments, such as antimuscarinics, do not always lead to sufficient improvement of the complaints and/or are often associated with considerable side effects resulting in treatment failure. In the case of failure or intolerable side effects, sacral neuromodulation (SNM) and botulinum toxin are minimally invasive and reversible alternatives. Currently, of these alternatives only SNM with InterStimTM therapy has FDA approval for use in OAB patients. This review attempts to provide an update on the current position of SNM and botulinum toxin in the second-line management of adults with idiopathic OAB, based on the available clinical evidence concerning the efficacy and safety. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20389150     DOI: 10.1159/000288223

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  10 in total

Review 1.  Selection of ideal candidates for neuromodulation in refractory overactive bladder.

Authors:  Ravi Kacker; Anurag K Das
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

Review 2.  Sacral nerve modulation in overactive bladder.

Authors:  John A Occhino; Steven W Siegel
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

Review 3.  Botulinum toxin for conditions of the female pelvis.

Authors:  Dominique El-Khawand; Salim Wehbe; Kristene Whitmore
Journal:  Int Urogynecol J       Date:  2013-01-24       Impact factor: 2.894

4.  Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms.

Authors:  Tariq F Al-Shaiji; Mai Banakhar; Magdy M Hassouna
Journal:  Adv Urol       Date:  2011-05-14

Review 5.  Overactive bladder - 18 years - Part II.

Authors:  Jose Carlos Truzzi; Cristiano Mendes Gomes; Carlos A Bezerra; Ivan Mauricio Plata; Jose Campos; Gustavo Luis Garrido; Fernando G Almeida; Marcio Augusto Averbeck; Alexandre Fornari; Anibal Salazar; Arturo Dell'Oro; Caio Cintra; Carlos Alberto Ricetto Sacomani; Juan Pablo Tapia; Eduardo Brambila; Emilio Miguel Longo; Flavio Trigo Rocha; Francisco Coutinho; Gabriel Favre; Jose Antonio Garcia; Juan Castano; Miguel Reyes; Rodrigo Eugenio Leyton; Ruiter Silva Ferreira; Sergio Duran; Vanda Lopez; Ricardo Reges
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

6.  Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.

Authors:  Nick Freemantle; David A Ginsberg; Rachael McCool; Kelly Fleetwood; Mick Arber; Kristin Khalaf; Clara Loveman; Quanhong Ni; Julie Glanville
Journal:  BMJ Open       Date:  2016-02-23       Impact factor: 2.692

7.  Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.

Authors:  D Sussman; A Yehoshua; J Kowalski; W Lee; J Kish; S Chaudhari; B Murray
Journal:  Int J Clin Pract       Date:  2017-03       Impact factor: 2.503

8.  Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Limin Liao; Qinggang Liu; Huiling Cong; Zhihui Xu; Enhui Li; Zhiliang Weng; Haihong Jiang; Ben Liu; Xiao Huang; Shujie Xia; Wei Wen; Juan Wu; Guowei Shi; Yang Wang; Peijun Li; Yang Yu; Zujun Fang; Jie Zheng; Ye Tian; Donghao Shang; Hanzhong Li; Zhongming Huang; Liqun Zhou; Yunxiang Xiao; Yaoguang Zhang; Jianlong Wang; Xiaodong Zhang; Peng Zhang; Dongwen Wang; Xuhui Zhang; Keji Xie; Bin Wang; Lulin Ma; Xiaojun Tian; Lijun Chen; Jinkai Dong
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

9.  Hyperpolarization-activated cation currents in medium-size dorsal root ganglion cells are involved in overactive bladder syndrome in rats.

Authors:  Chao Tan; Fei Yan; Li-Ping Yao; Jun-Ling Xing; Wei-Jun Qin; Kun Zhang; Guo-Jun Wu; Jian-Lin Yuan; Fei Liu
Journal:  BMC Urol       Date:  2020-09-02       Impact factor: 2.264

10.  OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).

Authors:  Osamu Yokoyama; Masashi Honda; Tomonori Yamanishi; Yuki Sekiguchi; Kenji Fujii; Takashi Nakayama; Takao Mogi
Journal:  Int J Urol       Date:  2020-01-20       Impact factor: 3.369

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.